• Explore /
  • Poster
  • / A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors.

A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors.

Abstract Poster

Authors

null

Jayesh Desai

Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

Jayesh Desai , Diwakar Davar , Sanjeev Deva , Bo Gao , Tianshu Liu , Marco Matos , Tarek Meniawy , Kenneth John O'Byrne , Meili Sun , Mark Voskoboynik , Kunyu Yang , Xinmin Yu , Xin Chen , Yan Dong , Hugh Giovinazzo , Shiangjiin Leaw , Deepa Patel , Tahmina Rahman , Yanjie Wu , Daphne Day

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Clinical Trial Registration Number

NCT04215978

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 2574)

DOI

10.1200/JCO.2023.41.16_suppl.2574

Abstract #

2574

Poster Bd #

416

Abstract Disclosures

Similar Posters

First Author: Jayesh Desai

First Author: Jayesh Desai

First Author: Michael Friedlander

First Author: Shunsuke Kondo